Generated by AI
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers. ArriVent BioPharma, Inc. concentrates on targeted oncology programs designed to address unmet medical needs, with particular emphasis on non-small-cell lung cancer and other solid tumors. Its current portfolio includes development of furmonertinib, an epidermal growth factor receptor mutant-selective therapy being evaluated across multiple EGFR mutation settings, as well as emerging pipeline candidates such as antibody-drug conjugates and other novel therapeutics. The company works through collaborations and in-licensing approaches to advance medicines from discovery into clinical development and, ultimately, patient access. Headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma, Inc. plays a specialized role in the oncology biopharmaceutical market by focusing on precision therapies for genetically defined cancer populations.
Website18 Campus Boulevard
Newtown Square, PA, 19073
United States
The latest articles about AVBP.
Summary of Oct 26's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Oct 26's posts. Generated by AI.
Investors talking about AVBP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.